Benzinga | Mar 30, 2021 08:21AM EDT

Exelixis Announces Enrollment Completion In Phase 3 COSMIC-313 Pivotal Trial Of Cabozantinib In Combination With Nivolumab And Ipilimumab Versus Nivolumab And Ipilimumab In Previously Untreated Advanced Renal Cell Carcinoma

Exelixis, Inc. (NASDAQ:EXEL) today announced that COSMIC-313, the phase 3 pivotal trial evaluating the combination of cabozantinib (CABOMETYX(r)), nivolumab (OPDIVO(r)) and ipilimumab (YERVOY(r)) versus the combination of nivolumab and ipilimumab in patients with previously untreated advanced intermediate- or poor-risk renal cell carcinoma (RCC), has completed enrollment. The primary endpoint of the trial is progression-free survival, and additional endpoints include overall survival and objective response rate.